- Previous Close
0.3810 - Open
0.3960 - Bid --
- Ask --
- Day's Range
0.3840 - 0.3960 - 52 Week Range
0.3600 - 1.2000 - Volume
13,379 - Avg. Volume
36,954 - Market Cap (intraday)
48.161M - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.53
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
www.benevolent.comRecent News: BAI.AS
View MorePerformance Overview: BAI.AS
Trailing total returns as of 1/6/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BAI.AS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BAI.AS
View MoreValuation Measures
Market Cap
47.41M
Enterprise Value
9.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.10
Price/Book (mrq)
0.42
Enterprise Value/Revenue
1.04
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.76%
Return on Equity (ttm)
-53.04%
Revenue (ttm)
4.87M
Net Income Avi to Common (ttm)
-51.41M
Diluted EPS (ttm)
-0.6500
Balance Sheet and Cash Flow
Total Cash (mrq)
38.08M
Total Debt/Equity (mrq)
6.31%
Levered Free Cash Flow (ttm)
-34.44M